Does the media prefer VTGN or PDSB?

In the previous week, VistaGen Therapeutics had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 3 mentions for VistaGen Therapeutics and 1 mentions for PDS Biotechnology. VistaGen Therapeutics' average media sentiment score of 0.00 equaled PDS Biotechnology'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VTGN or DYAI?

In the previous week, VistaGen Therapeutics had 1 more articles in the media than Dyadic International. MarketBeat recorded 3 mentions for VistaGen Therapeutics and 2 mentions for Dyadic International. VistaGen Therapeutics' average media sentiment score of 0.00 equaled Dyadic International'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, VTGN or APLM?

Apollomics has higher revenue and earnings than VistaGen Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VistaGen Therapeutics $1.27M 9.22 -$69.68M -$1.83 N/A Apollomics $8.50M 4.62 -$10.94M N/A N/A

Does the media refer more to VTGN or APLM?

In the previous week, VistaGen Therapeutics had 1 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for VistaGen Therapeutics and 2 mentions for Apollomics. Apollomics' average media sentiment score of 0.67 beat VistaGen Therapeutics' score of 0.00 indicating that Apollomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apollomics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, VTGN or RADX?

Radiopharm Theranostics has higher revenue and earnings than VistaGen Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VistaGen Therapeutics $1.27M 9.22 -$69.68M -$1.83 N/A Radiopharm Theranostics $2.35M 15.61 -$24.83M N/A N/A

Does the media prefer VTGN or FTH?

In the previous week, Sensei Biotherapeutics had 15 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 18 mentions for Sensei Biotherapeutics and 3 mentions for VistaGen Therapeutics. Sensei Biotherapeutics' average media sentiment score of 0.83 beat VistaGen Therapeutics' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

VistaGen Therapeutics (VTGN) Competitors

$0.26 -0.02 (-8.28%)

As of 04:00 PM Eastern

Compare

VTGN vs. PDSB, DYAI, APLM, RADX, and FTH

Should you buy VistaGen Therapeutics stock or one of its competitors? VistaGen Therapeutics's main competitors and comparable companies include PDS Biotechnology (PDSB), Dyadic International (DYAI), Apollomics (APLM), Radiopharm Theranostics (RADX), and Sensei Biotherapeutics (FTH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does VistaGen Therapeutics compare to PDS Biotechnology?

VistaGen Therapeutics (NASDAQ:VTGN) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

In the previous week, VistaGen Therapeutics had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 3 mentions for VistaGen Therapeutics and 1 mentions for PDS Biotechnology. VistaGen Therapeutics' average media sentiment score of 0.00 equaled PDS Biotechnology'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PDS Biotechnology has lower revenue, but higher earnings than VistaGen Therapeutics. PDS Biotechnology is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	9.22	-$69.68M	-$1.83	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

VistaGen Therapeutics currently has a consensus price target of $0.95, suggesting a potential upside of 260.12%. PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 1,131.02%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe PDS Biotechnology is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by insiders. Comparatively, 8.4% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PDS Biotechnology has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. VistaGen Therapeutics' return on equity of -133.02% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%
PDS Biotechnology	N/A	-346.02%	-102.36%

VistaGen Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market.

Summary

PDS Biotechnology beats VistaGen Therapeutics on 9 of the 14 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Dyadic International?

VistaGen Therapeutics (NASDAQ:VTGN) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

VistaGen Therapeutics currently has a consensus price target of $0.95, suggesting a potential upside of 260.12%. Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 201.45%. Given VistaGen Therapeutics' higher probable upside, equities research analysts plainly believe VistaGen Therapeutics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

VistaGen Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Dyadic International has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

In the previous week, VistaGen Therapeutics had 1 more articles in the media than Dyadic International. MarketBeat recorded 3 mentions for VistaGen Therapeutics and 2 mentions for Dyadic International. VistaGen Therapeutics' average media sentiment score of 0.00 equaled Dyadic International'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyadic International has higher revenue and earnings than VistaGen Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	9.22	-$69.68M	-$1.83	N/A
Dyadic International	$3.09M	11.74	-$7.36M	-$0.23	N/A

78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 20.9% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dyadic International has a net margin of -192.40% compared to VistaGen Therapeutics' net margin of -5,487.01%. VistaGen Therapeutics' return on equity of -133.02% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%
Dyadic International	-192.40%	-1,005.45%	-77.64%

Summary

Dyadic International beats VistaGen Therapeutics on 10 of the 15 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Apollomics?

VistaGen Therapeutics (NASDAQ:VTGN) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Apollomics has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. Apollomics' return on equity of 0.00% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%
Apollomics	N/A	N/A	N/A

In the previous week, VistaGen Therapeutics had 1 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for VistaGen Therapeutics and 2 mentions for Apollomics. Apollomics' average media sentiment score of 0.67 beat VistaGen Therapeutics' score of 0.00 indicating that Apollomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apollomics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apollomics has higher revenue and earnings than VistaGen Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	9.22	-$69.68M	-$1.83	N/A
Apollomics	$8.50M	4.62	-$10.94M	N/A	N/A

VistaGen Therapeutics currently has a consensus target price of $0.95, suggesting a potential upside of 260.12%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe VistaGen Therapeutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

VistaGen Therapeutics has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Apollomics beats VistaGen Therapeutics on 7 of the 13 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Radiopharm Theranostics?

VistaGen Therapeutics (NASDAQ:VTGN) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

VistaGen Therapeutics presently has a consensus target price of $0.95, suggesting a potential upside of 260.12%. Radiopharm Theranostics has a consensus target price of $11.00, suggesting a potential upside of 292.86%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts clearly believe Radiopharm Theranostics is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

VistaGen Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

Radiopharm Theranostics has higher revenue and earnings than VistaGen Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	9.22	-$69.68M	-$1.83	N/A
Radiopharm Theranostics	$2.35M	15.61	-$24.83M	N/A	N/A

Radiopharm Theranostics has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. Radiopharm Theranostics' return on equity of 0.00% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%
Radiopharm Theranostics	N/A	N/A	N/A

In the previous week, VistaGen Therapeutics had 3 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 3 mentions for VistaGen Therapeutics and 0 mentions for Radiopharm Theranostics. VistaGen Therapeutics' average media sentiment score of 0.00 equaled Radiopharm Theranostics'average media sentiment score.

Company	Overall Sentiment
VistaGen Therapeutics	Neutral
Radiopharm Theranostics	Neutral

78.4% of VistaGen Therapeutics shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Radiopharm Theranostics beats VistaGen Therapeutics on 10 of the 13 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Sensei Biotherapeutics?

VistaGen Therapeutics (NASDAQ:VTGN) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Sensei Biotherapeutics has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. VistaGen Therapeutics' return on equity of -133.02% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

In the previous week, Sensei Biotherapeutics had 15 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 18 mentions for Sensei Biotherapeutics and 3 mentions for VistaGen Therapeutics. Sensei Biotherapeutics' average media sentiment score of 0.83 beat VistaGen Therapeutics' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sensei Biotherapeutics has lower revenue, but higher earnings than VistaGen Therapeutics. Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	9.22	-$69.68M	-$1.83	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

VistaGen Therapeutics currently has a consensus target price of $0.95, suggesting a potential upside of 260.12%. Sensei Biotherapeutics has a consensus target price of $54.90, suggesting a potential upside of 92.16%. Given VistaGen Therapeutics' higher probable upside, analysts clearly believe VistaGen Therapeutics is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

VistaGen Therapeutics has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market.

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

VistaGen Therapeutics and Sensei Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get VistaGen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTGN vs. The Competition

Export

Metric	VistaGen Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.76M	$3.70B	$7.02B	$12.98B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.14	9.09	269.19	24.72
Price / Sales	9.22	1,255.18	588.76	97.77
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	0.29	17.66	11.27	6.42
Net Income	-$69.68M	-$13.25M	$3.45B	$347.03M
7 Day Performance	7.67%	5.36%	3.56%	2.49%
1 Month Performance	2.25%	-1.74%	-0.58%	-1.04%
1 Year Performance	-91.12%	61.36%	77.52%	23.22%

VistaGen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTGN VistaGen Therapeutics	1.6309 of 5 stars	$0.26 -8.3%	$0.95 +260.1%	-90.3%	$12.76M	$1.27M	N/A	40	Gap Up
PDSB PDS Biotechnology	1.6612 of 5 stars	$0.71 +4.1%	$9.00 +1,159.8%	-30.2%	$38.37M	N/A	N/A	20	Upcoming Earnings Analyst Upgrade
DYAI Dyadic International	2.6132 of 5 stars	$1.06 +1.0%	$3.00 +183.0%	+6.7%	$38.26M	$1.67M	N/A	7	News Coverage Upcoming Earnings
APLM Apollomics	0.8997 of 5 stars	$17.20 -0.3%	N/A	+209.9%	$37.87M	$8.50M	N/A	45	Gap Up
RADX Radiopharm Theranostics	2.9896 of 5 stars	$3.11 -1.3%	$11.00 +253.7%	-40.2%	$37.21M	$2.35M	N/A	N/A	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTGN) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VistaGen Therapeutics (VTGN) Competitors

VTGN vs. PDSB, DYAI, APLM, RADX, and FTH

How does VistaGen Therapeutics compare to PDS Biotechnology?

Summary

How does VistaGen Therapeutics compare to Dyadic International?

Summary

How does VistaGen Therapeutics compare to Apollomics?

Summary

How does VistaGen Therapeutics compare to Radiopharm Theranostics?

Summary

How does VistaGen Therapeutics compare to Sensei Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN vs. The Competition

VistaGen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VistaGen Therapeutics (VTGN) Competitors

VTGN vs. PDSB, DYAI, APLM, RADX, and FTH

How does VistaGen Therapeutics compare to PDS Biotechnology?

Does the media prefer VTGN or PDSB?

Which has better earnings and valuation, VTGN or PDSB?

Do analysts prefer VTGN or PDSB?

Do institutionals and insiders hold more shares of VTGN or PDSB?

Is VTGN or PDSB more profitable?

Which has more volatility and risk, VTGN or PDSB?

Summary

How does VistaGen Therapeutics compare to Dyadic International?

Do analysts prefer VTGN or DYAI?

Which has more volatility and risk, VTGN or DYAI?

Does the media refer more to VTGN or DYAI?

Which has stronger valuation and earnings, VTGN or DYAI?

Do institutionals and insiders hold more shares of VTGN or DYAI?

Is VTGN or DYAI more profitable?

Summary

How does VistaGen Therapeutics compare to Apollomics?

Is VTGN or APLM more profitable?

Does the media refer more to VTGN or APLM?

Which has higher earnings & valuation, VTGN or APLM?

Do analysts recommend VTGN or APLM?

Which has more risk and volatility, VTGN or APLM?

Do insiders and institutionals hold more shares of VTGN or APLM?

Summary

How does VistaGen Therapeutics compare to Radiopharm Theranostics?

Do analysts prefer VTGN or RADX?

Which has more volatility & risk, VTGN or RADX?

Which has higher valuation & earnings, VTGN or RADX?

Is VTGN or RADX more profitable?

Does the media favor VTGN or RADX?

Do insiders and institutionals have more ownership in VTGN or RADX?

Summary

How does VistaGen Therapeutics compare to Sensei Biotherapeutics?

Is VTGN or FTH more profitable?

Does the media prefer VTGN or FTH?

Which has better earnings and valuation, VTGN or FTH?

Do analysts recommend VTGN or FTH?

Which has more volatility & risk, VTGN or FTH?

Do institutionals and insiders hold more shares of VTGN or FTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN vs. The Competition

VistaGen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools